Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease

Is long-term adaptive deep brain stimulation (aDBS) tolerable and as effective and safe as continuous DBS (cDBS)?In this nonrandomized clinical trial with an open-label comparison between cDBS and aDBS, the primary outcome was met as the majority of participants receiving aDBS achieved a performance goal of good on-time (ie, time when symptoms were well controlled) without troublesome dyskinesia relative to stable cDBS therapy.Long-term aDBS provided tolerable, effective, and safe therapy in persons with Parkinson disease whose symptoms were previously stable while receiving cDBS.

Corresponding Author: Helen M. Bronte-Stewart, MD, MSE, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Room 254A, 453 Quarry Rd, Stanford, CA 94305 (hbs@stanford.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.